title: Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
abstract: BACKGROUND
  The overexpression of microRNA-21 (miR-21) in pancreatic cancer has been implicated in drug resistance to gemcitabine. Thus far, miR-21 has gained wide attention as a potential biomarker to predict the clinical response in patients with pancreatic cancer receiving gemcitabine. The aim of this study was to evaluate the predictive value of miR-21 expression, determined by locked nucleic acid in situ hybridization (LNA-ISH), in patients with pancreatic cancer who underwent adjuvant gemcitabine after curative surgery.
  
  
  METHODS
  Tumor miR-21 expression was analyzed via LNA-ISH and correlated with the clinical outcomes of the patients treated with adjuvant gemcitabine.
  
  
  RESULTS
  The overexpression of miR-21 in pancreatic cancer, determined by LNA-ISH, was significantly and independently associated with a shorter disease-free survival in patients who received adjuvant gemcitabine after curative resection.
  
  
  CONCLUSIONS
  The LNA-ISH analysis of miR-21 may serve as a significant predictor for gemcitabine resistance in patients with pancreatic cancer undergoing adjuvant gemcitabine after curative resection.
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan morinagas@kcch.jp.
authors.forename: Soichiro
authors.initials: S
authors.lastname: Morinaga
authors.affiliation: Department of Molecular Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Atsumi
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Murakawa
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yamaoku
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Aoyama
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Ueno
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
authors.affiliation: Department of Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yokose
authors.affiliation: Department of Molecular Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Miyagi
mesh_terms: D000368:Aged; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009841:Oligonucleotides / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D009841:Oligonucleotides; C477371:locked nucleic acid; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: MicroRNA-21; adjuvant monotherapy; gemcitabine; pancreatic cancer